Skip to main content

Table 4 Adjusted likelihood of receiving care concordant with the recommendations over two visitsa

From: Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations

  MTX monotherapy users (n = 741) Multiple-nbDMARD users (n = 995)
Patient factors
 Work status 1.28 (0.79–2.09) 1.94 (1.27–2.95)
 Private insurance 1.59 (1.06–2.39) 0.93 (0.65–1.33)
 Disease duration (per 5 years) 1.02 (0.92–1.13) 0.89 (0.83–0.96)
Provider factors
 Geographic region
  Northeast (reference) 1 1
  South 2.76 (1.42–5.36) 1.26 (0.75–2.12)
  Midwest 0.94 (0.50–1.79) 1.24 (0.72–2.12)
  West 1.18 (0.52–2.69) 1.33 (0.61–2.89)
Time period
 December 2008–November 2009 1.00 1.00
 December 2009–November 2010 0.93 (0.56–1.54) 0.79 (0.52–1.20)
 December 2010–November 2011 1.07 (0.63–1.83) 0.85 (0.54–1.36)
 December 2011-2/2013 0.85 (0.48–1.51) 0.50 (0.30–0.81)
  1. MTX methotrexate, nbDMARD nonbiologic disease-modifying antirheumatic drug
  2. aAdjusted for age, sex, baseline disease activity, prednisone use, physician practice years, and practice type, none of which were significantly associated with care, as well as clustering of patients by physician. Patient race/ethnicity (white vs. black vs. Asian vs. other) was included in the models but could not be evaluated, owing to confounding of this characteristic by site